Ronald J. Kamis

Law Practice

Mr. Kamis represents clients in patent prosecution and provides opinions of counsel in biotechnology, pharmaceutical and chemical technologies.

Mr. Kamis is licensed to practice in the District of Columbia and before the United States Patent Office.

Prior Experience

Mr. Kamis was a partner at Arent Fox LLP, partner and co-head of the Biotechnology and Pharmaceutical Patent Group at Baker & Daniels LLP, now Faegre Baker Daniels, and Of Counsel at Perkins Coie LLP before co-founding Prismatic Law Group, PLLC.

Mr. Kamis has prosecuted patent applications and provided opinions of counsel in the biotechnology, pharmaceutical and chemical industries for almost 20 years. Mr. Kamis has also counseled generic pharmaceutical companies regarding ANDA patent law issues.

Mr. Kamis has also counseled clients in intellectual property agreements and strategic alliances with multi-million dollar upfront cash payments and in multi-million dollar patent licensing litigations and arbitrations.

Representative Agreements

  • Strategic alliance agreements
  • Asset purchase agreements
  • Collaboration agreements
  • Research and development agreements
  • Complex IP license agreements
  • Reagents and antibody supply agreements
  • Distribution agreements
  • Material transfer agreements

Representative Technologies

  • Industrial polymers
  • Industrial chemical solvents
  • Industrial enzymes
  • Pharmaceutical drug formulations
  • Pharmaceutical small molecules
  • Antibody reagents
  • Peptide reagents
  • Nucleotide reagents
  • Diagnostic research assays
  • Stem cells
  • Therapeutic and diagnostic proteins and antibodies.


Juris Doctor
  • George Washington University
  • With Highest Honors
  • Member Law Review
Masters of Science
  • Johns Hopkins University
Bachelor of Arts
  • Duke University
  • Cum Laude

Representative Lectures

  • Biotechnology Industry Organization/Licensing Executives Society – “Intellectual Property & Negotiation Strategies” Seminars 2005/2008

Representative Articles

  • Law 360 “Carnegie Mellon: A Key Ruling For Biotech Patents” September 2008
  • Indianapolis Business Journal “Life Sciences Companies Can Find Freedom to Operate” 2007

Quoted In

  • DC Bar Cover Story “Stem Cells: The changing legal environment” January 2009